Article Search Engine

Taylor Hanson Rock & Roll Supergroup

Date: 2009-10-29T05:11:00.001-07:00
A new band called Tinted Windows is reportedly putting out an album this spring. Not news, right? What if we told you that the band features former Smashing Pumpkins guitarist James Iha, Fountains of Wayne’s Adam Schlesinger on bass, Cheap Trick’s Bun E. Carlos on drums, and Taylor Hanson, yes that Hanson, on vocals.

Both Born to Rock & Roll and The Daily Swarm are reporting that the “supergroup” Tinted Windows are planning a surprise unveiling shortly. In fact, Taylor Hanson’s local newspaper Tulsa World contacted his publicist about the story and got a reply that there is “no ‘official’ word” on the project. So this news is not “official,” but Hanson’s publicist has basically given it away.

Yes, Taylor Hanson’s joined a side project, including members of Cheap Trick, Smashing Pumpkins and Fountains of Wayne. The band has named itself Tinted Windows. On Wednesday, Taylor Hanson posted a letter to his fan club via the Hanson.net fansite and made the news official: “Over the last couple years, Adam Schlesinger from Fountains of Wayne and James Iha have been working on this project — we first met Adam years ago when we were making ‘Middle Of Nowhere.’ ”

That longtime friendship turned into a collaboration with Taylor Hanson on vocals, Iha and Schlesinger on bass, and legendary Cheap Trick member Bun E. Carlos on drums.
Taylor Hanson was quick to clarify, “For me and the other guys in the group this is a great project that is an addition to who we are in our core bands.” Also, while at home in Tulsa, the brothers have been busy entertaining Adam Green of The Moldy Peaches and comedic musician Weird Al Yankovic, among others, while working on the Hanson album. Writing and recording is expected to continue over the next few months, Taylor Hanson wrote.

---

Taylor Hanson

Date: 2009-10-29T04:48:00.000-07:00
Taylor Hanson, the middle man of Hanson, is the lead singer of the group. Most fans find Taylor Hanson a major heartthrob. He was born on March 14, 1983 (Pisces). Taylor Hanson enjoys touring. He thinks it's fun and wild and a great opportunity. He gets to experience all kinds of things, he had fun playing cricket in Australia. These are things he says he'll cherish for a lifetime.

Taylor Hanson or Tay as he likes to be called, can't get over what fans will go through to see them and the things they make for them. Girls in Taiwan followed them all over, taking cabs everywhere. On girl sent a pinata of a UFO.

Tay wants to be able to look back on his life and remember all the fun he had in these first years of popularity. He thinks you should work hard at what you're doing and have fun doing it.

As far as the people Tay has met, one of his favorite singers, Jewel, and also Gwen Stefani. Tay doesn't have a girlfriend at the moment, and sometimes responds to fan mail. Hint, hint. You can read all about Taylor Hanson in a book called:

"Taylor Hanson: Totally Taylor Hanson " by Nancy Krulik, published by Pocket Books. It's in bookstores now.

---

Development of an AIDS Vaccine

Date: 2009-09-24T05:37:00.000-07:00
As the HIV/AIDS epidemic continues to exact its punishing toll, the need to intensify our efforts to find an effective vaccine is greater than ever. There is a broad consensus that the best way to accelerate the development of an AIDS vaccine is by conducting multiple vaccine trials simultaneously in industrialized and developing countries.

A serious HIV-vaccine effort will require additional funding to promote the development of new vaccines for testing and to strengthen sites in developing countries where candidate vaccines will be tested and ultimately deployed. If the international community realizes that an HIV vaccine is one of the best examples of what we term "a global public good", and assumes responsibility to support its development with an urgent sense of commitment, only then will the quest for an AIDS vaccine be closer to fruition.

Unquestionably, no more important goal exists in medical research today than the development of an AIDS vaccine. Last year, AIDS, caused by H.I.V., was the infectious disease that killed the most people around the world, and the epidemic is not abating.

Can we make an AIDS vaccine? One might think that, because we have produced vaccines against most human viral infections, of course we can make one against AIDS. But H.I.V. is a new story. History is a poor guide when it comes to this killer. The task of making an AIDS vaccine is evident: Such a vaccine must stimulate the immune system to produce both antibodies and C.TL.s, preferably ones that are more effective than those created naturally when someone is infected with H.I.V That is a tall order.

The Merck vaccine failure is a "deep disappointment and a scientific setback for the AIDS vaccine field," the AIDS Vaccine Advocacy Coalition said. However, the nonprofit group added that "while this is a disappointment, it is in no way the end of the search for an AIDS vaccine."

In 1963 he founded the Jonas Salk Institute for Biological Studies, a center devoted solely for medical and scientific research. His last years were devoted to finding a vaccine against AIDS. Dr. Jonas Salk died on June 23, 1995. He was 80 years old.

---

Whisperings of Ovarian Cancer

Date: 2009-09-17T16:24:00.000-07:00
Ovarian cancer is referred to as the silent killer because symptoms tend to be noticed when cancer is in an advanced stage. Despite this belief, research has demonstrated that women are experiencing identifiable symptoms up to a year before an ovarian cancer diagnosis. A statement on the National Ovarian Cancer Coalition ([NOCC], 2006) Web site says "Ovarian cancer ... it whispers, so listen!" Listening to the whispers as well as giving the whisper volume so it can be heard is essential.

Women experiencing the vague but identifiable symptoms of ovarian cancer need the voice to respond to the whispering of their bodies, collectively and individually. Listening to women and identifying their symptoms is an obvious task, but nurses also need to consider women's ways of knowing and the strength of women's voices to optimize screening, early detection, and timely care for ovarian cancer. It is a theoretical framework that can be used to emphasize the importance of listening to women as they are screened in any healthcare setting, especially for the early symptoms of ovarian cancer.

The purpose of this descriptive qualitative study is to examine personal stories of ovarian cancer within the framework of WWK to understand how women voice their whisperings of ovarian cancer and their interactions with healthcare providers. A review of the literature was conducted using the CINHAL[R] database. To begin the search, the key words, ovarian cancer, cancer screening, female, and early detection, resulted in 116 articles. The literature included discussions of evidence-based screening practices, recommended diagnostic tests, and the Ovarian Cancer Symptom Index.

Because WWK is the guiding framework for the study, the key words, ovarian cancer and women's ways of knowing and ovarian cancer and intuition were used to guide the literature search. Ovarian cancer still is elusive because no useful diagnostic test for the general population is available. Rather a combination of diagnostic tools are used to screen for ovarian cancer, but they are not used to screen all women. Because no equivalent to the mammogram or Pap smear currently exists for detecting ovarian cancer.

The accuracy of those modalities is limited and has not proven to be effective in identifying ovarian cancer in the early stages. USPSTF listed a D recommendation for routine ovarian cancer screening, which means that screening of asymptomatic women is ineffective or the harms outweigh the risks. Population-based screening for ovarian cancer is not recommended by the American College of Obstetricians and Gynecologists.

---

Therapy in Non-Small Cell Lung Cancer

Date: 2009-09-17T16:19:00.000-07:00
Context.-The development of targeted therapy provides an exciting prospect for treatment of advanced non- small cell lung cancer. In the last few years the epithelial growth factor receptor has emerged as one of the most important targets in very selected patients.

Objective.-To review current data on the role of the targeted therapy in advanced non-small cell lung cancer and offer some perspectives for the practitioner.

Conclusions.-Despite the remarkable development of targeted therapies in advanced non-small cell lung cancer, there is not yet a real improvement in overall survival.

Gene therapy is an exciting prospect for treatment of lung cancer because genes can be transduced into cancer cells to correct genetic lesions or inactivate oncogenes.

Epidermal growth factor receptor mutations are present in about 10% of cases of non-small cell lung cancers in the United States and Europe and in about 30% to 50% of non-small cell carcinomas in Asians. More than 50% of adenocarcinomas with bronchioloalveolar features that arise in nonsmokers have EGFR mutations.

Mutations in codons 12 and 13 of the KRAS gene, present in 30% of non-small cell lung cancers, and a history of cigarette smoking are usually associated with resistance to TK-Is. Recent data suggest that EGFR mutations and KRAS mutations are mutually exclusive in non- small cell lung cancer.

---